Product image of Irbesartan Rowa (Irbesartan) supplied by GNH India

Irbesartan Rowa

Active Ingredient:
Irbesartan
Origin:
EU

Irbesartan Rowa (Irbesartan)

Irbesartan, the active ingredient in Irbesartan Rowa, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It lowers blood pressure by blocking AT1 receptors and is used to treat hypertension in adult patients.\n\nGNH India supplies Irbesartan Rowa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Rowa Pharmaceuticals Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Irbesartan acts on the renin‑angiotensin‑aldosterone system to control elevated blood pressure and protect the kidneys.\n\n- Hypertension: reduces systolic and diastolic pressure, helping prevent cardiovascular complications.\n- Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes with proteinuria.\n- Heart failure (adjunct therapy): improves symptoms and may reduce hospitalisation when combined with standard heart‑failure regimens.

How It Works

  • Irbesartan selectively antagonises angiotensin II type 1 (AT1) receptors on vascular smooth muscle, adrenal gland and renal tubular cells. By blocking these receptors, it prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vasodilation, reduced sodium and water retention, and ultimately lower arterial pressure.

Side Effects

  • Common Side Effects:\n- Dizziness: sensation of light‑headedness, especially after standing.\n- Headache: mild to moderate pain in the head region.\n- Fatigue: feeling unusually tired or weak.\n- Upper respiratory infection: mild cold‑like symptoms.\n- Hyperkalemia: elevated blood potassium levels, often asymptomatic.\n\nSerious or Rare Side Effects:\n- Angioedema: rapid swelling of face, lips, tongue or throat requiring emergency care.\n- Acute renal failure: sudden loss of kidney function, indicated by reduced urine output.\n- Severe hyperkalemia: potassium levels >6.0 mmol/L, risking cardiac arrhythmia.\n- Hepatic injury: elevated liver enzymes or jaundice.\n- Hypotension: marked drop in blood pressure causing faintness.

Precautions & Warnings

  • Irbesartan should be used with careful monitoring and patient education.\n\n- Blood pressure monitoring: check regularly to ensure therapeutic control.\n- Renal function assessment: evaluate serum creatinine and eGFR before and during therapy.\n- Serum potassium surveillance: monitor especially if combined with potassium‑sparing agents.\n- Hepatic impairment caution: dose may need adjustment in patients with liver disease.\n- Pregnancy avoidance: discontinue if pregnancy is confirmed due to fetal risk.\n- Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

  • Irbesartan may interact with several drug classes, requiring clinical vigilance.\n\nMajor Interactions (Avoid):\n- Aliskiren (in diabetes): combined use can increase renal impairment and hyperkalemia.\n- Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous hyperkalemia.\n- ACE inhibitors: concurrent use raises angioedema risk.\n- NSAIDs: may blunt antihypertensive effect and affect renal function.\n- Lithium: increased lithium levels leading to toxicity.\n\nModerate Interactions (Monitor Closely):\n- Thiazide diuretics: may enhance hypotensive effect, requiring dose titration.\n- Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood‑pressure lowering.\n- CYP3A4 inhibitors (e.g., fluconazole): modest increase in irbesartan plasma concentrations.\n- CYP3A4 inducers (e.g., rifampin): may reduce irbesartan effectiveness.\n- Antidiabetic agents: improved glycaemic control may necessitate dose adjustment.

Frequently Asked Questions

Irbesartan Rowa contains the ARB irbesartan and is prescribed to lower high blood pressure (hypertension). It is also used to slow kidney damage in patients with type 2 diabetes who have proteinuria, and may be added to heart‑failure regimens to improve symptoms.

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal tissue. By preventing angiotensin II from binding, it stops vasoconstriction and aldosterone release, leading to relaxed vessels, reduced sodium retention, and lower arterial pressure.

The exact dose of Irbesartan Rowa is determined by the prescribing clinician based on the individual’s blood‑pressure level, kidney function and other medical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Irbesartan is classified as contraindicated in pregnancy because it can harm the developing fetus. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative therapies with their healthcare provider.

To order Irbesartan Rowa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers or diuretics, ARBs target the renin‑angiotensin system directly, providing an alternative mechanism for patients who need additional or substitute therapy.

Irbesartan Rowa tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Irbesartan Rowa is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

The most serious risks include angioedema (swelling of the face, lips, tongue or throat), severe hyperkalemia (high blood potassium), and acute renal failure. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of kidney function, or signs of high potassium such as muscle weakness.

Irbesartan Rowa should not be used by individuals with known hypersensitivity to irbesartan or any ARB component, pregnant women, or patients with severe liver impairment without medical supervision. Caution is also advised for those with existing renal dysfunction or elevated potassium levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT